<DOC>
	<DOCNO>NCT00905060</DOCNO>
	<brief_summary>The Phase 2 trial single-arm investigation design evaluate safety , survival , immune response patient treat autologous tumor-derived heat shock protein peptide-complex ( HSPPC-96 ) administer 25 Î¼g per dose inject intradermally weekly 4 consecutive week monthly follow standard treatment radiation temozolomide .</brief_summary>
	<brief_title>HSPPC-96 Vaccine With Temozolomide Patients With Newly Diagnosed GBM</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Presurgery tissue acquisition Inclusion criterion 1 . &gt; equal 18 year old 2 . Life expectancy great 12 week . 3 . Able read understand inform consent document ; must sign informed consent 4 . Must suspect diagnosis Glioblastoma Multiforme surgical intent resect least 90 % enhance disease 5 . Must eligible postsurgical treatment radiotherapy temozolomide Postradiation therapy/prevaccine eligibility Inclusion criterion 1 . Agree use contraception abstain sexual activity time consent 1 month end study drug administration 2 . Negative serum pregnancy test female patient childbearing potential 3 . Patients histologically proven , nonprogressive glioblastoma multiforme ( GBM ) 4 . Patient must receive standard care radiation temozolomide therapy 5 . Must undergone least 90 % resection ( determined PI ) measure postoperative magnetic resonance imaging ( MRI ) scan , T1weighted contrast scan , CT scan clinically indicate , perform within 72 hour surgery 6 . All radiotherapy must discontinue least 2 week 5 week prior first plan vaccine administration 7 . Availability least 4 dos vaccine ( least 4 vial clinical administration produce tumor provide ) 8 . Karnofsky functional status rating &gt; equal 70 9 . Adequate bone marrow function include absence lymphopenia ( ANC &gt; 1,500/ mm3 ; ALC &gt; 500/mm3 ; platelet count &gt; 100,000/mm3 ) , adequate liver function ( serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [ AST ] , alanine amino transferase [ ALT ] , alkaline phosphatase &lt; 2.5 time institutional upper limit normal [ IULNs ] bilirubin ( total ) &lt; 1.5 mg*IULN ) , adequate renal function ( BUN creatinine &lt; 1.5 time IULNs Presurgery tissue acquisition 1 . Current diagnosis Human Immunodeficiency Virus ( HIV test require per protocol ) 2 . Any prior diagnosis cancer concurrent malignancy , exception adequately treat nonmetastatic situ carcinoma uterine cervix nonmetastatic nonmelanoma skin cancer unless complete remission therapy disease minimum 5 year 3 . Any systemic autoimmune disease ( e.g. , Hashimoto 's thyroiditis ) and/or history primary secondary immunodeficiency 4 . Any prior therapy glioma 5 . Planned use current use investigational therapy treatment glioma Postradiation therapy/prevaccine Exclusion 1 . Inability comply studyrelated procedure 2 . Prior diagnosis cancer concurrent malignancy , exception adequately treat nonmetastatic situ carcinoma uterine cervix nonmetastatic nonmelanoma skin cancer unless complete remission therapy disease minimum 5 year 3 . Current active use chemotherapy ( except temozolomide ) immune therapy 4 . Contrast MRI finding ( CT scan MRI clinically contraindicate ) consistent progression per protocol define modified RANO criteriaProgression prior vaccination determine Principal Investigator 5 . Patients active uncontrolled infection 6 . Evidence bleed diathesis 7 . Unstable severe intercurrent medical condition 8 . Female patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Newly Diagnosed Glioblastoma Multiforme , vaccine</keyword>
</DOC>